Newbury Daylilies

Main Menu

  • Home
  • Newbury
  • Slough
  • Wokingham
  • Maidenhead
  • Banking

Newbury Daylilies

Header Banner

Newbury Daylilies

  • Home
  • Newbury
  • Slough
  • Wokingham
  • Maidenhead
  • Banking
Banking
Home›Banking›Kodak to Move Forward in Drug Ingredient Manufacturing Amid US Loan Problems

Kodak to Move Forward in Drug Ingredient Manufacturing Amid US Loan Problems

By Lisa Scuderi
March 9, 2021
0
0


Eastman

Kodak Co.

KODK -4.04%

Managing Director Jim Continenza has defended his company’s handling of an interrupted US loan and said Kodak will continue to move forward in manufacturing pharmaceutical ingredients whether or not it receives government assistance.

Mr. Continenza’s comments at Monday’s WSJ Tech Live conference follow a tumultuous time for the former photo giant. In July, the company has reached a deal for $ 765 million with the US government to produce pharmaceutical ingredients, only to have its plans unfold quickly.

At the conference, Mr. Continenza declined to discuss the status of the loan, which the agency involved put on hold shortly after announcing it.

Shortly after announcing the planned agreement in July, the Securities and Exchange Commission started an investigation on how the company disclosed the loan, and several Democratic-led congressional committees have announced an investigation into the deal. The federal agency that had partnered with Kodak, the US International Development Finance Corp., suspended the deal and its own watchdog opened an internal review.

At the conference, Mr. Continenza acknowledged the uproar, recalling that “about two to three days later, he started going mad”. Asked whether the company acted too quickly to close the deal, Mr Continenza said, ‘it has come up quickly, but I think it needs to do that too,’ citing concerns concerning the dependence of the United States on foreign countries for drugs. He said Kodak had done its best to manage the deal, while admitting that his company was understaffed, especially amid the coronavirus pandemic.

Kodak CEO Jim Continenza told WSJ’s Darren Everson that a continued Trump presidency won’t make a difference for the company at WSJ Tech Live 2020.

Kodak has since conducted its own investigation into its handling of loan plans. This review revealed that the company did not violate any laws relating to the disclosure of the loan. Kodak’s review, however, revealed several governance issues at play. One issue was a donation of Kodak shares made by George Karfunkel, a member of the Kodak board of directors, on the same day that the stock price rose. peaked after the government’s announcement. Mr. Karfunkel donated stock, worth $ 116 million, to a religious charity he founded.

Asked at the Wall Street Journal conference about Mr. Karfunkel and whether he would stay on the company’s board, Mr. Continenza declined to answer. “He will be responsible for what he does,” Continenza said. Mr. Karfunkel could not be reached immediately for comment.

Another issue that emerged from the proposed transaction was Kodak’s timing for granting stock options to executives, including Mr. Continenza. Asked about the subsidies, Continenza said he had not sold any shares and that the subsidies “should not be the center of attention.”

The Journal reported earlier the Kodak plans were spearheaded by Peter Navarro, business advisor to President Trump, who worked with the International Development Finance Corp., a federal bank-like agency.

In late July, Trump administration officials said the Kodak alliance would help accelerate domestic production of drugs capable of treating a variety of medical conditions and ease the United States’ reliance on foreign sources in countries such as China and India. The needs were pressing, administration officials said, in light of the coronavirus pandemic, which quickly left the United States scrambling to treat those infected.

Kodak Pharmaceuticals plans to manufacture critical pharmaceutical ingredients which have been identified as essential but which have fallen into chronic national shortage.


Photo:

Matt Rourke / Associated Press

As part of the plan, Kodak would produce ingredients for a number of generic drugs, including the antimalarial drug hydroxychloroquine that President Trump has touted in the treatment of coronavirus, although researchers have said it has no benefit. as early outpatient treatment.

On the day the plan was announced, Mr. Trump called it “one of the most significant deals in the history of the US pharmaceutical industry.” My administration has entered into a historic agreement with a large American company.

Mr. Navarro, on Fox News, later called the Kodak plans a “blockbuster” the president designed.

After the deal was put on hold amid the SEC investigation, Mr Trump sought to distance himself, saying he was not involved.

The DFC was an unusual choice to manage such a program. Typically, the agency provides loans in developing countries, but in May it received approval to support the Covid-19 response.

More from the WSJ Tech Live event

Write to Rachael Levy at [email protected]

Copyright © 2020 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8


Related posts:

  1. Budget 2021: Why we need to look at tuition loans
  2. Opendoor Announces Fourth Quarter and Full Year 2020
  3. Sleeping estate in Westchester County, NY could play a leading role in Trump tax cases
  4. Finance: Return of the Refi: CLO Rate Adjustment Transactions After COVID-19 | Alston & Bird

Recent Posts

  • How did Berkshire MPs vote in the recent Brexit bill?
  • How the Thames seduced the smart set of the 20th century
  • Walter E. Arties, founder of Breath of Life, dies at 80
  • Alexander Devine Children’s Hospice: Teen Movie Virtual Tour
  • What is the dress code for Henley Regatta and where can you park?

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • March 2021

Categories

  • Banking
  • Maidenhead
  • Newbury
  • Slough
  • Wokingham
  • Terms and Conditions
  • Privacy Policy